Biocon Biologics Gains Full Global Control Of Hulio

Biocon Biologics Ltd, a subsidiary of Biocon Ltd, announced that it has obtained full and exclusive global rights for Hulio (adalimumab biosimilar) from Fujifilm Kyowa Kirin Biologics (FKB). This strategic move grants Biocon Biologics end-to-end control over the product’s development, manufacturing, and commercialization, enhancing its position in the global biosimilars market.

Key Highlights

• Biocon Biologics assumes complete manufacturing and commercialization responsibility for Hulio worldwide
• The agreement includes payment of technology license fees and royalties to FKB
• Commercial production will commence following technology transfer and regulatory approvals
• Hulio is a biosimilar to Humira, one of the world’s top-selling biologics used in autoimmune conditions
• This acquisition strengthens Biocon Biologics’ portfolio, which already spans multiple biosimilars across oncology, immunology, and diabetes care
• The move aligns with Biocon’s strategy to expand its global footprint and deliver affordable biologics to patients worldwide

This development marks a significant milestone for Biocon Biologics, positioning the company as a stronger player in the competitive biosimilars landscape while reinforcing its commitment to accessible healthcare solutions.

Sources: InvestyWise, Biocon Official Release, Biocon Biologics Website